22
Berkeley, CA, 94720; e: dbautista@berkeley.edu Roviezzo et al., 2015) . S1P signaling 77 via S1P Receptor 1 (S1PR1) facilitates the migration, recruitment, and activation of immune cells 78 (Matloubian et al., 2004; Cyster and Schwab, 2012) , and S1P is also thought to influence epithelial cell 79 differentiation and cell division via the action of several other S1PRs (Schüppel et al., 2008; Japtok et al., 80 2014 ). Intriguingly, expression of both S1PR1 and S1PR3 has been reported in the somatosensory ganglia 81 S1PR3 triggers neuronal excitation and pain are unclear. Likewise, it is not known whether S1P also acts 88 as a pruritogen to cause itch. 89 90 S1P has been examined in a variety of inflammatory skin diseases and disease models. There is evidence 91 supporting both protective and pathogenic effects of S1P signaling in mouse and human chronic itch and 92 inflammatory diseases. In humans, elevated serum S1P is correlated with disease severity in both 93 psoriasis and systemic sclerosis (Castelino and Varga, 2014; Checa et al., 2015; Thieme et al., 2017) . 94
Furthermore, ponesimod, an S1PR modulator and blocker of S1P signaling, appears to be promising for 95 psoriasis treatment in humans (Brossard et al., 2013; Vaclavkova et al., 2014; Krause et al., 2017) . In 96 contrast, in the imiquimod mouse model of psoriasis, it was observed that topical S1P exerts protective 97 effects (Schaper et al., 2013) , and in dogs with atopic dermatitis, it was found that S1P levels are 98 decreased in lesional skin (Bäumer et al., 2011) . However, in the Nc/Nga mouse model of dermatitis and 99 the TNCB mouse model of dermatitis, the S1P Receptor modulator fingolimod, which downregulates 100 activity of S1PRs 1, 3,4, and 5, was found to exert protective effects (Kohno et al., 2004; Sugita et al., 101 2010 ). In light of these studies, we asked whether S1P can act as an acute pruritogen in mice. 102
103
We set out to answer this question by examining the role of S1P in acute itch, and by dissecting the 104 downstream molecular mechanisms in somatosensory neurons responsible for S1P-evoked behaviors and 105 neuronal activation. Here we show that S1P can act as both a pruritogen and algogen. Our study is the first 106 to identify a role for S1P signaling in acute itch, and to elucidate the downstream molecular mechanisms by 107 which nociceptive and pruriceptive somatosensory neurons detect and respond to S1P. Our findings 108 demonstrate the contribution of S1P signaling to cutaneous itch and pain, and have important applications 109 for the design and use of S1PR modulators as therapeutics for chronic itch and pain diseases. we first tabulated the absolute value of the Pearson's correlation r between expression of each S1P 128 pathway gene in turn (Fam57b, Ppargc1a, Spns1, Spns2, Sphk2, S1pr3, S1pr1, Esrrb, Esrrg, Lrp2) and 129 itch behavior (Morita et al., 2015) , and calculated the median of these correlation values, r true . We then 130 drew 10 random genes from the set of all 16,220 genes with detected expression and computed the 131 median correlation as above using this null set, r null . Repeating the latter 10,000 times established a null 132 distribution of median correlations; we took the proportion of resampled gene groups that exhibited (r true ≥ 133 r null ) as an empirical p-value reporting the significance of enriched correlation between expression and itch 134 in the genes of the S1P pathway. 135
136

Mouse behavior 137
Itch and acute pain behavioral measurements were performed as previously described (Wilson et al., 138 2011). Mice were shaved one week prior to itch behavior. Compounds injected: 200 nM, 2 µM, 10 µM S1P 139 (Tocris, Avanti Polar Lipids), in PBS with Methanol-PBS vehicle controls. Fresh S1P was resuspended in 140 methanol and single-use aliquots were prepared and dried under nitrogen gas prior to use. Pruritogens 141 were injected using both the neck/rostral back model (20 µl), and the cheek model (20 µl) of itch, as 142 previously described (Wilson et al., 2011) . Behavioral scoring was performed while blind to experimental 143 condition and mouse genotype. All scratching and wiping behavior videos were recorded for 1 hour and 144 scored for either the first 30 minutes (scratching) or the first five minutes (wiping). Bout number, time spent 145 scratching, and bout length were recorded for scratching behavior. Wiping was recorded as number of 146 wipes. 147
148
For radiant heat hypersensitivity behavior, S1P was injected intradermally into the plantar surface of the 149 hindpaw (20 µl). Radiant heat paw withdrawal latencies, before and after application of compound or 150 vehicle were performed as previously described (Tsunozaki et al., 2013; Morita et al., 2015) using the 151
Hargreaves test system (IITC Life Science). Mice were injected with compound of interest into the hind 152 paw, paw withdrawal latencies were measured 15 min pre-and 20 min-30 min post-injection. Heat-evoked 153 responses included fast paw withdrawal, licking/biting/shaking of the affected paw, or flinching. Mice were 154 allowed to acclimate on platform for 1 hour before injection. The radiant heat source raised the platform 155 temperature to 39.8 °C within 5 seconds, and to 60 °C within 10 seconds, as measured by a fast 156 temperature probe (Physitemp). 157
158
Wherever possible, wild-type littermate controls were used in behavioral experiments. Mice were singly 159 housed one week prior to all behavioral experiments. All mice were acclimated in behavioral chambers on 160 the 2 subsequent days for at least 1 hour prior to treatment for itch/pain behavior and radiant heat. Age-161 matched or littermate male mice were used for all behavioral studies. Mice were tested in 4-part behavior 162 chambers (IITC Life Science) with opaque dividers (Tap Plastics). Itch and acute pain behavior was filmed 163 from below using high-definition cameras. 164
165
In situ hybridization (ISH) 166
ISH was performed as previously described. Fresh DRG were dissected from 8-12 week old mice, flash 167 frozen in OCT embedding medium, and sectioned at 14 µm onto slides. ISH was performed using 168 DAPI-positive cells were circled and their fluorescence intensity (AFU) for all channels was plotted against 174 cell size using IgorPro software. Co-labeling analysis was performed using ImageJ. Intensity thresholds 175
were set based on the negative control staining slide. Cells were defined as "co-expressors" if their 176 maximum intensities were greater than the threshold for both the Type 1 and Type 6 probe channels. 177
178
Cell culture 179
Cell culture was carried out as previously described (Wilson et al., 2011) . Briefly, neurons from dorsal root 180 ganglia of 2-8 week old male and female mice, or trigeminal ganglia from P0-P4 neonates, where 181 indicated, were dissected and incubated for 10 min in 1.4 mg ml−1 Collagenase P (Roche) in Hanks 182 calcium-free balanced salt solution, followed by incubation in 0. experiments. An age-matched wild-type control was also prepared and imaged the same day for 192 experiments on knockout neurons. Cells were loaded for 60 min at room temperature with 10 µM Fura-2AM (where N = number of mice used) for calcium imaging experiments where multiple independent days of 219 imaging were performed, and mean ± SD for all other experiments (N = number of wells or number of 220 mice). A one-or two-way ANOVA followed by the Sidak's, Dunnett's or Tukey's post hoc tests (where 221 appropriate) was employed. Number of mice or samples required to attain significance was not calculated 222 beforehand and was based on numbers used in similar behavioral studies. For behavioral experiments, 223 mice were randomly assigned to treatment groups by the individual who blinded the experimenter. For 224 behavioral experiments, every effort was made to ensure equal numbers of mice of each genotype were 225 used for each experiment (where appropriate), and that treated and control groups were of identical or 226 near-identical size. Significance was labeled as: n.s., not significant, p ≥ 0.05; *p < 0.05; **p < 0.01; ***p < 227 0.001. 228
229
Results
230
S1P triggers itch via S1PR3
231
Our group previously harnessed natural variation in somatosensory behaviors among genetically distinct 232 mouse strains to identify candidate transducers in dorsal root ganglion (DRG) somatosensory neurons 233 (Morita et al., 2015) . Analysis of this dataset revealed that members of the sphingosine 1-phosphate (S1P) 234 synthesis and signaling pathways (Fig. 1a) were expressed in somatosensory neurons in a manner that 235 correlated with itch behaviors (Fig. 1b) . Previous studies have shown that S1P promotes acute pain 236 (Camprubi-Robles et al., 2013) and thermal sensitization via S1P Receptor 3 (S1PR3), and is required for 237 normal mechanical pain sensitivity (Hill et al., 2018). Here, we sought to address the specific contribution of 238 S1P/S1PR3 signaling to S1P-evoked itch behaviors. 239
240
We first asked whether exogenous S1P can trigger itch using the cheek assay, which allows for 241 simultaneous discrimination of pain-evoked wiping and itch-evoked scratching in mice (Shimada and 242 LaMotte, 2008). Injection of 2-10 µM S1P triggered acute nocifensive behaviors, as previosuly shown 243 (Camprubi-Robles et al., 2013; Hill et al., 2018). However, we also observed robust scratching in these 244 animals ( Fig. 1c) . Intriguingly, 200 nM S1P elicited robust scratching behaviors (Fig. 1c) , but no pain 245 behaviors. Scratching behaviors developed with an average latency of 4 minutes 29 seconds ± 1 minute 37 246 seconds and persisted for at least 30 minutes. We also observed that injection of 200 nM S1P into the 247 rostral back triggered itch behaviors with an average scratching time of 66 ± 18.1 seconds, which was 248 significantly greater than scratching evoked by vehicle (0.1% methanol-PBS; 14.5 ± 2.88 seconds; Fig. 1d) . 249
To begin to elucidate the mechanisms underlying these effects, we focused on the S1P receptor S1PR3, 250 which is required for S1P-evoked pain and pain hypersensitivity (Camprubi-Robles et al., 2013; Hill et al., 251 2018). Assessment of itch behavior in S1pr3 -/-mice revealed significantly attenuated S1P-evoked 252 scratching, indistinguishable from vehicle injection (10.6 ± 12.3 s versus 6.3 ± 6.2 s, respectively; Fig. 1d ). 253
Furthermore, in a previous report, we observed no defects in itch responses to the pruritogens chloroquine 254 and histamine in S1pr3 -/-mice (Hill et al., 2018). These data suggest that S1PR3 is the primary receptor by 255 which S1P signals in somatosensory neurons to drive itch. Our findings show that S1P can act as a 256 pruritogen, selectively triggering itch at nanomolar concentrations, whereas at micromolar concentrations, 257 S1P acts both as a pruritogen and algogen, triggering itch and pain. Our discovery that S1PR3 is required 258 for S1P-evoked itch is consistent with previous studies showing that S1P-evoked acute pain (Camprubi- 
S1PR3 is functional and expressed in a subset of pruriceptors 265
We next asked whether S1PR3 is functional and expressed in itch neurons. Calcium imaging of S1P 266 responses in wild-type mouse somatosensory neurons revealed that 1 µM S1P activates 34.2% of all 267 neurons, which fall into two main populations: 22.6% (66.1% of S1P + neurons) are TRPV1 + /TRPA1 + 268 neurons, which are capsaicin-and allyl isothiocyanate (AITC)-sensitive, and 11.6% (33.9% of S1P + 269 neurons) are TRPV1 + /TRPA1 -neurons, which are capsaicin-sensitive and AITC-insensitive (Fig. 2a,b) . 270
Neurons which were responsive to both AITC and S1P exhibited an EC 50 for S1P of 102 nM, and were 271 activated by lower S1P concentrations (10 nM) than neurons which were responsive to capsaicin and S1P 272 (EC 50 = 155 nM) and showed robust responses to 100 nM S1P (Fig. 2c) Zhu et al., 2017) . In keeping with our hypothesized role for S1P in itch, 80% of 277 chloroquine-responsive MrgprA3 + neurons responded to S1P (Fig. 2b) . We also observed a population of 278 S1P-sensitive neurons which were sensitive to the pruritogen histamine (23.6% of S1P-sensitive neurons; 279 Fig. 2b) . We conclude that S1P activates thermal nociceptors that express TRPV1 and pruriceptors that 280 express TRPA1 and TRPV1. 281
282
To pursue further the mechanism by which S1P acts in somatosensation, we examined the effects of 283 pharmacological blockade of S1PR3 and S1PR1 on S1P-evoked calcium responses. Incubating cells with 284 the S1PR3-selective antagonist TY 52156 attenuated S1P-evoked calcium transients with an IC 50 of 0.4 285 µM (Fig. 2d) . In contrast, the S1PR1-selective antagonist W146 had no discernable effect on S1P 286 responses at a range of concentrations that exceed reported inhibitory concentrations (70-80 nM) for this 287 drug ( 
TRPV1+/TRPA1
+ DRG neurons, whether this receptor is expressed in pruriceptors was unknown. To 294 investigate this, we performed co-in situ hybridization (co-ISH) of S1pr3 with Mrgpra3, which encodes the 295 chloroquine receptor that marks a neuronal subpopulation required for some forms of acute and chronic 296 itch (Liu et al., 2009 ). We found that 35.1% of Mrgpra3 + cells express S1pr3 and 11.6% of S1pr3 + cells 297 express Mrgpra3 (Fig. 2f) . The differing proportions of S1pr3 + /Mrgpra3 + neurons in our ISH and of 298 S1P + /chloroquine + neurons in our calcium imaging studies (Fig. 2b ) may reflect a difference between intact 299 DRG versus cultured DRG neurons, and/or the sensitivity of mRNA expression versus calcium imaging 300 assays. In summary, our calcium imaging and co-ISH data, along with our previous findings, reveal two 301 main populations of small-diameter S1pr3 + neurons: 1) Trpv1 + thermal nociceptors and, 2) Trpa1 + cells, 302 including a subset of Mrgpra3 + pruriceptors. These results dovetail with our finding that S1PR3 is required 303 for S1P-evoked itch (Fig. 1d) . 304
S1P triggers neuronal activation in distinct subsets of nociceptors and pruriceptors 305
We next sought to identify components downstream of S1PR3 underlying S1P-evoked calcium transients 306 in cultured mouse somatosensory neurons. S1P responses were mediated solely by calcium influx, as 307 chelation of extracellular calcium abolished all responses (Fig. 3a) , suggesting that S1P triggers the 308 opening of plasma membrane cation channels. We also observed similar results with application of 309 Ruthenium Red (Fig. 3b) , a blocker of a number of calcium-permeable ion channels, including Transient 310
Receptor Potential (TRP) channels. 311
312
Since we observed that all S1P responsive neurons expressed TRPA1 and/or TRPV1 , and these channels 313 either channel mediated S1P-evoked neuronal activation. Neurons isolated from mice lacking both TRPA1 317 and TRPV1 exhibited greatly attenuated S1P-evoked calcium responses, similar to those evoked by 318 vehicle (Fig. 3c) . Intriguingly, we found the percentage of S1P-responsive neurons was partially attenuated 319 in neurons from Trpv1 -/- (Fig. 3d) and Trpa1 -/-single knockout mice (Fig. 3e) . Such genetic effects were 320 mirrored by pharmocological blockade of these channels: the TRPV1 antagonist capsazepine (50 µM; 321 CPZ) or the TRPA1 antagonist HC-030031 (50 µM; HC) were sufficient to fully block capsaicin or AITC 322 responses, respectively, and resulted in a significant, though partial, attenuation of neuronal S1P 323 responses (Fig. 3f) . 324
325
To test whether TRPA1 and/or TRPV1 are required for S1P-evoked neuronal excitability, we turned to 326 current-clamp whole cell electrophysiology to examine action potential (AP) firing. For this purpose, we 327 isolated and cultured DRG neurons from the S1pr3 mCherry reporter mouse, which produces a functional 328 S1PR3-mCherry fusion protein (Sanna et al., 2016) , and examined their changes in membrane potential in 329 response to S1P. Our experiments revealed that 1 µM S1P elicited AP firing in both the capsaicin-sensitive 330 and AITC-sensitive S1PR3+ populations of sensory neurons (Fig. 3g-h, top) . We next used a 331 pharmacological approach to investigate the role of TRPV1 and TRPA1 in S1P-evoked AP firing. TRPV1 332 (Fig. 3g) . Likewise, 334 blockade of TRPA1 with HC resulted in a decreased proportion of cells which fired in response to S1P and 335 the expected complete loss of AITC-evoked firing (Fig. 3h) . These results suggest that TRPV1 and TRPA1 336 directly contribute to S1P-evoked neuronal activation and AP firing. Combined with our calcium imaging 337 studies using TRP channel inhibitors and A1/V1 knockout neurons, our data show that TRPA1 and TRPV1 338 are required for S1P-evoked neuronal activation in distinct populations of somatosensory neurons. 339 340 S1PR3 utilizes distinct G-protein coupled pathways to activate subsets of somatosensory neurons 341
We used a pharmacological approach to investigate the mechanisms by which S1PR3 signals to TRPA1 342 and TRPV1. We first focused on phospholipase C (PLC), a known target of the S1PR3 signaling partner G q 343 2017), we hypothesized that PLC signaling could be required for S1P-evoked calcium responses in 348 sensory neurons. This notion bore out, in that inhibition of PLC signaling using the drug U73122 349 significantly decreased the percentage of neurons that displayed S1P-evoked calcium responses (Fig. 4a) . 350
This effect was most pronounced in the TRPA1 -population of S1P-responsive neurons (Fig. 4b,c) , but had 351 only a small effect on the TRPA1 + population (Fig. 4b,c) . Next, given that GPCR signaling via G βγ can 352 activate TRPA1 (Wilson et al., 2011) , we asked if G βγ signaling could also play a role in S1P-evoked 353 calcium responses. We observed a significant reduction in the percentage of neurons responding to S1P 354 upon blockade of G βγ activity using the drug gallein (Fig. 4a) . And in contrast to PLC inhibition, gallein's 355 effects were more robust in the TRPA1 + population and were minimal in the TRPA1 -population (Fig. 4b,c) . 356
Blockade of both pathways using U73122 and gallein resulted in a significant loss of all neurons responsive 357 to S1P (Fig. 4a) , irrespective of population (Fig. 4b,c) . Thus, S1PR3 can signal in two different sensory 358 neuronal subtypes (TRPA1 + /TRPV1 + and TRPA1 -/TRPV1 + neurons) in a concentration-dependent manner, 359 using distinct molecular signaling molecules (G βγ and PLC, respectively). 360
S1P evokes itch and pain behaviors via distinct TRP channels 361
Here we have shown that TRPA1 and TRPV1 are required for S1P-evoked neuronal exicitation and 362 calcium responses in pruriceptors and nociceptors. We thus tested the requirement of TRPA1 and TRPV1 363 to S1P-evoked itch and pain behaviors. We observed that S1P evoked robust heat hypersensitivity in wild-364 type and Trpa1 -/-mice, but not in Trpv1 -/-mice (Fig. 5a) . Similarly, 10 µM S1P triggered acute nocifensive 365 behaviors (wiping) in wild-type and Trpa1 -/-mice, but not in Trpv1 -/-mice (Fig. 5b) . Finally, we examined 366 S1P-evoked itch behaviors in wild-type, Trpa1
-/-and Trpv1 -/-mice using the rostral back model. In contrast 367 to our pain data, 200 nM S1P evoked robust scratching behaviors in wild-type and Trpv1 -/-mice, but not in 368
Trpa1
-/-mice (Fig. 5c) . These data support a model whereby TRPV1 selectively mediates S1P-evoked 369 acute pain and heat hypersensitivity, whereas TRPA1 selectively mediates S1P-evoked acute itch (Figure 370 ). Yet the cellular and molecular targets of S1P in 377 these disorders are largely unknown. Here, we show that S1PR3 is required for S1P-evoked pain and itch, 378 highlighting the potential for a direct contribution of S1P to sensitization, pain and/or itch in these diseases. 379
380
There is much interest in exploring the therapeutic potential of S1PR signaling in chronic pain and itch. 381
However, little was known about the role of S1PRs in sensory neurons and their role in itch. We now show 382 that S1P activates pruriceptors and triggers itch via S1PR3 and TRPA1. In mice, we found that injection of 383 0.2 µM S1P triggered acute itch behaviors while concentrations at or above 2 µM triggered both itch and 384 pain. S1PR3-deficient mice displayed a complete loss of S1P-evoked acute itch (Fig. 1d) Our findings suggest sensory neuronal S1PR3 may play roles in disorders already linked to S1P signaling. 388 Although S1P is produced by nearly every cell type, blood plasma contains the highest levels of S1P (low 389 micromolar), and S1P is secreted in large amounts by activated mast cells ( Our observations that the TRPA1 + population is activated by lower doses of S1P than the TRPA1 -404 population (Fig. 2c) , and that itch behaviors are triggered by doses which are non-painful (Fig. 1c) , 405 supports a recent study showing that both zebrafish and mouse pruriceptors are significantly more 406 sensitive to stimuli than nociceptors. This increased sensitivity results in selective recruitment of 407 pruriceptors over nociceptors by the same agonist in a dose-dependent manner, such that lower 408 concentrations of agonist selectively trigger itch and higher concentrations trigger both itch and pain 409 (Esancy et al., 2018). While that study observed these effects using the weak TRPA1 activator imiquimod 410 and the strong TRPA1 activator AITC, we see similar effects using varying concentrations of S1P (Fig. 1) . It 411 is interesting that our results in the cheek model mirror theirs, and lend support to a peripheral "population 412 coding" model wherein low intensity stimuli can selectively drive pruriceptor activation and itch while high 413 intensity stimuli activate both nociceptors and pruriceptors to drive pain and itch. We show that more 414 S1P/S1PR3 signaling is required to activate nociceptors and drive pain behaviors than is required to 415 activate pruriceptors and trigger itch. voltage-sensitive channels. While S1P may activate multiple channels in somatosensory neurons, we have 425 used pharmacological and genetic tools to show that TRPA1 and TRPV1 are essential for initiating S1P-426 evoked excitation and are differentially required for S1P-evoked itch and pain, respectively. Our 427 experiments using G-protein pathway inhibitors suggest that S1PR3 utilizes distinct G-protein pathways to 428 activate TRPA1 and TRPV1, which may contribute to differential initiation of itch and pain behaviors, and 429 support a recent study suggesting that S1PR3 can couple to a number of downstream G-protein signaling 430 pathways (Flock et al., 2017) . While it is difficult to probe G-protein coupled pathways in vivo, it is tempting 431 to speculate that the different signaling pathways downstream of S1PR3 in vitro may account for the 432 differential engagement of pain and itch pathways by S1P. 433 434 While S1P signaling in general has been implicated in a variety of inflammatory skin diseases, our data 435 suggest that S1PR3 may be an important contributor to cutaneous itch associated with these disorders. 436
Fingolimod, which decreases S1PR activity at S1PRs 1,3,4 and 5 with varying affinity, has proven to be 437 effective in reducing inflammation in mouse models of allergic contact dermatitis and in spontaneous 438 ponesimod, which inhibits S1PR1, decreases disease severity in psoriasis patients (D'ambrosio et al., 440 2016). In contrast, one study found that topical S1P can exert protective effects in mouse models of 441 psoriasis and allergic contact dermatitis (Schaper et al., 2013) . This is surprising, as one would expect S1P 442 to promote inflammation, rather than inhibit it. However, this may be due to the diverse roles different 443 S1PRs may play in different cell types. For example, S1PR2 exerts proliferative effects on keratinocytes 444 (Japtok et al., 2014), whereas S1PR1 directs immune cell migration into tissues (Matloubian et al., 2004) . 445
Our findings suggest that S1P/S1PR3 signaling may play an important role in itch sensations associated 446 with these skin disorders. we propose neuronal S1P/S1PR3 signaling as a potential target for the treatment of inflammatory pain and 453 itch. We showed previously that loss of S1PR3 can block inflammatory pain without affecting immune cell 454 recruitment, and that a selective S1PR3 antagonist can ameliorate inflammatory hypersensitivity, 455
suggesting that S1PR3-specific blockers may be effective for treating pain (Hill et al., 2018). Our finding 456 that S1P can act as a pruritogen also suggests a role for S1P/S1PR3 in chronic itch, where circulating S1P 457 levels have been found to be significantly increased in human psoriasis patients (Checa et al., 2015; 458 Myśliwiec et al., 2016). While we and others have demonstrated the relevance of S1PR3 signaling to 459 chronic pain, it will be essential to explore the role of S1P/S1PR3 signaling in chronic itch models to 460 ascertain its pathological relevance. Our data supports a key role for S1PR3 in activation of pain and itch 461 neurons and may inform rational design of S1P and S1PR modulators to treat pain, itch, and inflammatory 462 (Left) Putative pruriceptor that responds to both chloroquine and S1P; (Center) putative pruriceptor or nociceptor which responds to both AITC and S1P; (Right) Putative thermal nociceptor which responds to S1P and capsaicin but not AITC. b. Venn diagram demonstrating overlap of neuronal subpopulations activated by capsaicin, AITC, histamine (HIS; 100 µM) chloroquine, and S1P. Relative proportion of overlap represents % overlap as calculated from ratiometric calcium imaging data (N = 4,000 neurons). c. Dose-response curve showing proportion of DRG neurons responding to varying concentrations of S1P. Concentrations used: 1, 10, 50, 100, 200, 1000, and 10,000 nanomolar (N = 2 animals). Colored traces indicate proportion of neurons responding to S1P and AITC or S1P and capsaicin at indicated concentrations. d. S1P-evoked calcium transients in DRG neurons are inhibited by the selective S1PR3 antagonist TY 52156. Black dotted line indicated sigmoidal fit from which IC 50 was derived (N = 2 animals). Error bars represent mean ± SD. f. S1P-evoked calcium transients in DRG neurons are not inhibited by the selective S1PR1 antagonist W146 (N = 2 animals). Error bars represent mean ± SD. f. Co-ISH of S1pr3 (green) with Mrgpra3 (magenta) in sectioned whole DRG from adult wild-type mice. Third column: overlay. Scale bar = 100 µm. Images were acquired using a 10x air objective. Arrows indicate cells showing co-expression of both markers. or 50 µM Capsazepine and subsequently exposed to 1 µM S1P followed by 1 µM capsaicin, indicated by lines. (Top) Recording from a neuron that responded to S1P and CAP; (Middle) A neuron that responded to neither S1P nor CAP; (Bottom) a neuron that responded to S1P but not CAP. In these experiments, 5 of 6 S1PR3+ cells which received vehicle responded to S1P and 5 of 6 responded to CAP; 3 of 8 cells which received Capsazepine responded to S1P and 0 of 8 cells responded to CAP (N = 3 animals). h. Whole cell current-clamp recordings of S1PR3+ DRG neurons from S1pr3 mCherry/+ animals pre-treated for 5-10 minutes with Vehicle (1% DMSO in Ringer's) or 50 µM HC-030031 and subsequently exposed to 1 µM S1P followed by 100 µM AITC, indicated by lines. (Top) Recording from a neuron that responded to S1P and AITC; (Middle) A neuron that responded to neither S1P nor AITC; (Bottom) a neuron that responded to S1P but not AITC. In these experiments, 4 of 5 S1PR3+ cells which received vehicle responded to S1P and 2 of 5 responded to AITC; 4 of 11 cells which received HC-030031 responded to S1P and 0 of 11 cells responded to AITC (N = 3 animals). . The effects of S1P on thermal hypersensitivity and acute pain and itch. a. Elevated S1P 1) elicits thermal hypersensitivity and acute pain via S1PR3-dependent activation of TRPV1, which requires PLC activity (top) and 2) elicits itch-evoked scratching via S1PR3-dependent activation of TRPA1, which requires G βγ (bottom).
